83-2271-57　［受注停止］KRIBIOLISA Ivacaftor （KALYDECO） ELISA 1 x 96 wells　KOD1017

特徴

• Description：Enzyme Immunoassay for the Quantitative Determination of Ivacaftor in
• human serum and plasma
• Ivacaftor is a cystic fibrosis transmembrane conductance regulator （CFTR） potentiator used alone or in
• combination products to treat cystic fibrosis in patients who have specific genetic mutations that are
• responsive to the medication.
• Ivacaftor （also known as Kalydeco or VX-770） is a drug used for the
• management of Cystic Fibrosis （CF）.
• It is manufactured and distributed by Vertex Pharmaceuticals.
• It was
• approved by the Food and Drug Administration on January 31, 2012.
• Ivacaftor is administered as a
• monotherapy and also administered in combination with other drugs for the management of CF.
• About the kit：
• - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％
• - Ready to use with a standard protocol with break-apart pre-coated wells
• - Validated as per US FDA guidelines for Bioassays
• - Optimized for matrix effects to ensure higher sensitivity.
• - Shelf life： 1 year
• The method employs the competitive enzyme immunoassay technique.
• In the first step, samples and
• standards along with the Ivacaftor： HRP conjugate is pipetted and incubated.
• Both the standard/sample and
• Ivacaftor： HRP conjugate compete with CFTR （cystic fibrosis transmembrane conductance regulator （ATP-
• binding cassette sub-family C, member 7）, which is pre-coated onto microwells.
• Free HRP conjugate will be
• removed by a washing step.
• In the second step, TMB substrate is added to microwells and color develops
• inversely proportionally to the amount of Ivacaftor present in the samples or standards.
• Color development is
• then stopped by addition of stop solution.
• Absorbance is measured at 450 nm.